

SPECS Drug Repurposing Set

SPECS Drug Repurposing Set

6000 Drug repurposing set (Phase 1-3, preclinical and launched) built by The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA and gathered/assembled by Specs.

SPECS:

“Drug repurposing is the application of existing drugs for use in a different disease. Such an exercise holds many advantages over traditional drug discovery processes. It reduces the costs and development time and, since these drugs already have successfully passed clinical trials, detailed information on their pharmacology, formulation, dose, and potential toxicity is available. Despite all the benefits, a comprehensive library of compounds that have reached phase 1 clinical trials is not commercially available.”

Broad Institute:

“The Drug Repurposing Hub is a curated and annotated collection of FDA-approved drugs, clinical trial drugs, and selected pre-clinical tool compounds. Because the compounds are annotated and well characterized, the collection is a novel tool to explore known biological targets and pathways, and a powerful way to discover new biological insights, better understand disease mechanisms, and discover new activities of existing molecules. Finally, when the disease biology is poorly understood, the compounds can be used in phenotypic screens to identify a new indication for a known drug.”